BACKGROUND: Prior studies examining the value of lymph node (LN) dissection (LND) in patients with urothelial carcinoma of the upper urinary tract (UTUC) have produced conflicting results. The objective of the current study was to assess the relationship between LN yield and survival among patients undergoing radical nephroureterectomy (RNU). METHODS: The National Cancer Data Base was used to identify patients with non-metastatic UTUC who were treated with RNU between 2004 and 2012. The association between LN yield and overall survival (OS) was assessed using Cox proportional hazards regression, with adjustment for patient, tumor, and facility characteristics. RESULTS: Of the 14,472 patients, 2926 (20%) underwent LND. The median yield was 2 LNs (interquartile range 1-6 LNs). Among the entire cohort and the LN-negative (pN0) 
INTRODUCTION
Urothelial carcinoma of the upper urinary tract (UTUC) is a rare but highly aggressive malignancy. UTUC has a propensity for early metastatic spread to the regional lymph nodes (LNs), with LN metastases being found at the time of radical nephroureterectomy (RNU) in approximately 20% to 25% of patients with T2 tumors (those invading into the muscularis propria) and as many as 60% of those with T3 or T4 tumors (those invading into the renal parenchyma or perinephric/ periureteric fat and adjacent organs, respectively).
1 LN metastases increase the risk of cancer-specific mortality nearly 3-fold such that approximately two-thirds of patients with positive LNs (pN1) die of their disease within 5 years of undergoing surgery. 2 Although the presence of LN metastases is an important prognostic factor in patients with UTUC and the extent of LN dissection (LND) has been shown to be associated with survival in the related disease of UC of the bladder, 3 the use of LND in patients with UTUC has not been standardized. This may be due to the lack of an established association between LND and survival in this patient population. Obtaining level 1 evidence of a therapeutic benefit for LND in patients with UTUC is a daunting proposition due in part to the rarity of the disease and the lack of consensus regarding standard dissection templates. Meanwhile, observational studies have produced somewhat conflicting findings. Specifically, although a recent analysis of the Surveillance, Epidemiology, and End Results (SEER) registry found a positive association between LN yield and cancer-specific survival (CSS), 4 an earlier multi-institutional study reported an association among patients with negative LNs (pN0) only. 5 Given the ongoing uncertainty regarding the prognostic and therapeutic value of LND in patients with UTUC, we set out to define the association between LN yield and survival using the National Cancer Data Base (NCDB).
MATERIALS AND METHODS
The NCDB is a joint project of the American Cancer Society and the American College of Surgeons that collects data from cancer registries at Commission on Cancerdesignated hospitals, which comprise approximately onethird of all US hospitals but diagnose approximately 70% of cancer cases nationwide. 6 It contains information pertaining to patient and tumor characteristics, the initial course of treatment, and vital status at the time of last follow-up, but lacks data pertaining to tumor recurrence or cause of death. Institutional Review Board approval for the current study was waived because de-identified data were used.
The primary objective of the study was to assess the relationship between LN yield, which was used as a surrogate for the extent of LND, and overall survival (OS) among patients with UTUC who were undergoing RNU. Secondary objectives were to assess the relationship between LN status (pN0 vs pN1 vs pNX [LNs not assessed]) and OS among the entire cohort, and to identify patient, tumor, and facility characteristics associated with receipt of LND, LN yield, and LN positivity. The study population was defined as patients aged 18 years who were diagnosed with UTUC between 2004 and 2012 and were treated with RNU (23,884 patients). We excluded patients with metastatic disease at the time of diagnosis (790 patients), those with a prior cancer diagnosis (8092 patients), and those with missing data pertaining to whether LND was performed (648 patients), LN yield (3 patients), or follow-up time (538 patients). The remaining 14,472 patients, 2926 of whom underwent LND, were included in the analyses. The median follow-up among survivors was 3.5 years (interquartile range [IQR] 2.0-5.7 years).
Survival analyses were performed using Cox proportional hazards regression. Logistic regression was used to model LN positivity and receipt of LND, whereas zerotruncated, negative binomial regression was used to model LN yield. Covariates included age (modeled as a continuous variable), sex, comorbidity burden as measured by the Deyo modification of the Charlson Comorbidity Index (categorized as 0 vs 1 vs 2), race (white vs black vs other), insurance status (private vs Medicare vs other), ZIP code-level income (quartiles), urbanicity of the patient's county of residence (metropolitan vs non-metropolitan), facility designation (academic comprehensive cancer program vs other), location (Northeast vs Midwest vs South vs West), and annual RNU volume (continuous), year of diagnosis (modeled as a set of indicator variables), time from diagnosis to RNU (continuous), tumor site (renal pelvis vs ureter), laterality, grade (well or moderately differentiated vs poorly differentiated or anaplastic), pathologic T classification (T1 [no invasion or invasion of subepithelial connective tissue only] vs T2 vs T3 vs T4), surgical margin status, and receipt of chemotherapy (none vs neoadjuvant vs adjuvant). Time from diagnosis to RNU was classified as missing if the date of diagnosis was the same as the date of RNU. With respect to the coding of tumor grade, although the AJCC Collaborative Staging System tumor grading scheme that is used by the NCDB differs from the World Health Organization/International Society of Urological Pathology (WHO/ISUP) grading scheme for UC, a prior analysis of cases of UC of the bladder in the SEER database, which uses the same grading scheme as the NCDB, found that 98% of WHO/ISUP low grade tumors and 97% of WHO/ISUP high grade tumors were classified as well or moderately differentiated and poorly differentiated or anaplastic, respectively. 7 Because it was hypothesized that the relationship between LN yield and outcomes may not be linear, LN yield was also modeled using restricted cubic splines with knots placed at 2, 6, and 18 LNs (corresponding to the 50th, 75th, and 95th percentiles of LN yield). Knots were placed at these points because the LN yield distribution was positively skewed. 8 We also tested whether the associations between the number of total and negative LNs removed and survival differed according to LN status (pN0 vs pN1) via interaction terms. To assess whether the number of positive and negative LNs had independent prognostic value among pN1 patients, these counts were also modeled separately. We likewise assessed the relationship between LN density (number of positive LNs divided by the total number of LNs removed) and survival among the pN1 subgroup.
Multiple imputation by chained equations was used to account for missing covariate data, the frequency of which varied from 27% for time from diagnosis to RNU to 10% for grade to < 4% for all other covariates. To account for the clustering of outcomes at the facility level, we calculated robust standard errors for all models. We confirmed that LN yield did not violate the proportional hazards assumption. All statistical tests were 2-sided, and P values < .05 were considered to be statistically significant. Statistical analyses were performed using SAS Original Article 
RESULTS
The median age of the patients included in the analysis was 71 years (IQR 63-79 years) and 57% were male (Table 1) . Approximately 69% of tumors were located in the renal pelvis, 64% were high grade, and 47% were classified as T2. LND was performed in 2926 patients (20%), with the median yield being 2 LNs (IQR 1-6 LNs; Figure 1 ). Increasing age and comorbidity burden were associated with a lower probability of undergoing LND and a lower LN yield on multivariable analysis, although the associations with LN yield did not reach conventional levels of statistical significance (Table 2) . Conversely, treatment at an academic facility and more recent year of diagnosis were found to be positively associated with receipt of LND and LN yield. Patients with left-sided tumors and ureteric tumors were more likely to undergo LND and have more LNs removed. Higher tumor grade and T classification were found to be associated with a higher likelihood of undergoing LND but not LN yield (although patients with T4 tumors had, on average, higher LN yields than those with non-muscleinvasive disease, those with T2 and T3 tumors did not). LN metastases were identified in 26% of patients who underwent LND. Tumor characteristics that were found to be independently associated with LN positivity included tumor location in the renal pelvis and left side, high tumor grade, increasing T classification, and positive surgical margins (Table 3) . LN yield was also an independent predictor of LN positivity: among patients who had 1 LN removed, the adjusted probability of detecting LN metastases was 24%, a figure that increased in a non-linear fashion before peaking at 31% at a yield of approximately 15 LNs (Fig. 2) .
A total of 5816 deaths occurred during follow-up. The 5-year OS probabilities were 61% (95% confidence interval [95% CI] 59%-64%), 24% (95% CI 20%-27%), and 59% (95% CI 58%-60%), respectively, for patients classified as pN0, pN1, and pNX. The presence of LN metastases was found to be an independent predictor of higher all-cause mortality (multivariable hazard ratio [HR] 1.89 for pN1 vs pN0 patients, 95% CI 1.64-2.17 [P<.001]) ( Table 4 ). All-cause mortality among patients who did not undergo LND was lower than that among pN1 patients (HR 0.56, 95% CI 0.49-0.64 [P<.001]) but was not significantly different from that among pN0 patients (HR 1.05, 95% CI 0.97-1.14 [P 5 .21]). Other disease characteristics that were found to be independent predictors of shorter survival included ureteric location, high tumor grade, increasing T classification, and positive surgical margins. Receipt of adjuvant chemotherapy was associated with longer survival among the entire cohort and the pN1 subgroup, but not the pN0 subgroup (Table 4).
Among the 2926 patients who underwent LND, a higher LN yield was associated with higher OS, with a 6% decrease in the hazard for every 5 LNs removed (multivariable HR 0.94, 95% CI 0.89-1.00 [P 5 .034]). Modeling LN yield using splines suggested that the relationship between LN yield and OS was non-linear (P 5 .022 for non-linearity and P 5 .010 for overall non-linear association), with the nadir hazard occurring at a yield of approximately 15 LNs (HR 0.75 for 15 LNs vs 1 LN removed, 95% CI 0.62-0.90).
The test for interaction between LN yield and LN status was found to be highly significant (P 5 .001), indicating that the relationship between LN yield and OS differed between pN0 and pN1 patients. In contrast, there was no evidence of a statistically significant interaction between negative LN count and LN status (P 5 .08). Subgroup analyses confirmed that a higher LN yield was associated with higher OS among pN0 patients (HR 0. Original Article 
DISCUSSION
In an analysis encompassing a large, diverse, and contemporary group of patients with UTUC treated at over 1,000 US hospitals, we found that LND constitutes a part of surgical management in only approximately 20% of such patients. Furthermore, the majority of patients who do undergo LND receive limited resections with low LN yields. These findings are likely a reflection of the ongoing uncertainty regarding the therapeutic value of LND in patients with UTUC. The low median LN yield and high rate of positivity in the LNs sampled suggests that the attitude toward LND during RNU at the majority of centers is that of a staging procedure, with selective removal of suspicious LNs ("node plucking") being performed without interest in extending the dissection template in the setting of positivity. Given that standard cross-sectional imaging has limited accuracy in predicting pathologic LN positivity in patients with UTUC, 9,10 LND has long been the gold standard for LN staging, which is a key determinant of prognosis. 11, 12 The adequacy of sampling is a central issue in surgical LN staging and the question of the number and location of LNs required for adequate staging is highly relevant. The results of the current study demonstrate that the likelihood of identifying positive LNs continues to increase up to a yield of approximately 15 LNs, suggesting that if LND was performed for staging purposes then the majority of cases in the current series were undersampled.
There currently is a lack of consensus regarding the value of LND in the surgical management of patients with UTUC, which likely stems from inconsistent and occasionally contradictory findings reported by prior studies. 4, 5 One of the largest of these studies, from the Upper Tract Urothelial Carcinoma Collaboration, analyzed outcomes among 552 patients with UTUC who were treated at 13 centers worldwide. 5 This study reported finding an association between higher LN yield and lower cancerspecific mortality among pN0 patients. Among the entire, unstratified cohort, a higher LN yield was found to be associated with a lower risk of disease recurrence on multivariate analysis (HR 0.97 per 1 LN removed [P 5 .04]), although there was only a non-significant association between LN yield and CSS (HR 0.97 per 1 LN removed; [P 5 .12] ). The significantly larger number of patients in the current study is the likely reason why we were able to detect an association between LN yield and survival whereas the previous study had not. 5 Alternately, because the relationship between LN yield and OS appears to be non-linear, the strength of the association detected in any study assuming a linear relationship would be partially dependent on the LN yield distribution within the study sample. Although it is likewise possible that the discrepant results could be due to the fact that the current study used OS instead of CSS as the outcome of interest, this is made less likely by the fact that we adjusted our multivariable analyses for both age and comorbidity burden. Furthermore, a recent population-based study using the SEER registry likewise found a higher LN yield to be an independent predictor of higher CSS among patients with UTUC who were undergoing RNU. 4 These findings further support the belief that the link between a more extensive LND and longer survival in this population is a causal one.
The association between an increasing number of negative LNs and survival within both the pN0 and pN1 subgroups is interesting to note. Among patients who are classified as pN0, an increasing number of LNs removed and examined decreases the potential for the misclassification of those individuals with LN metastases as pN0. The prognostic value of an increasing number of negative LNs among pN1 patients may be explained in a similar fashion, in that it more accurately defines the true burden of LN metastases by way of LN density. Although LN density has been previously established as an important prognostic factor in patients with pN1 UC of the bladder, 13, 14 to the best of our knowledge this concept has yet to be validated within the setting of UTUC. Previously, a small series demonstrated that a LN density 30% was an independent predictor of higher cancer-specific mortality, 15 although this finding was not replicated in a follow-up study. 16 An alternate explanation for the association between the number of negative LNs and survival among pN0 patients is that a thorough LND can be truly therapeutic if it eradicates unidentified microscopic foci of metastatic disease that are missed on routine pathologic examination. This hypothesis is supported by a recent study that reported finding micrometastatic disease using immunohistochemistry in 14% of patients with UTUC who were initially classified as having pN0 disease but later presented with disease recurrence. 17 Irrespective of the putative therapeutic mechanisms, the findings of the current study offer evidence that a thorough LND has clinical value because it improves the accuracy of LN staging, which may offer benefits for informed management strategies such as the use of adjunctive therapies. Patients in the current study with LN metastases were more likely to receive adjuvant chemotherapy, and although there currently is no level 1 evidence of a benefit of perioperative chemotherapy in patients with UTUC undergoing RNU, 18 we did find an association between receipt of adjuvant chemotherapy and higher OS among pN1 but not pN0 patients. More accurate LN staging also might alter postsurgical surveillance strategies in ways that could impact the identification, characterization, and reporting of disease recurrence.
Although the results of the current study suggest that a more thorough LND at the time of RNU is associated with longer survival, our study does not answer the lingering question as to which LN regions should be dissected to maximize the staging accuracy and therapeutic benefit of LND. To our knowledge, few studies have attempted to delineate the patterns of metastatic spread of UTUC to the regional LNs within the retroperitoneum. In a recent multi-institutional study of 73 pN1 patients, the majority of patients with right-sided renal pelvic and proximal ureteric tumors were found to have hilar and paracaval LN metastases, whereas those with left-sided tumors most often had metastases to the hilar and paraaortic LNs. 19 Involvement of the interaortocaval LNs was common in patients with right-sided tumors and paracaval LN metastases but not those with left-sided tumors. Although validation of these findings is required, an earlier observational study that compared patients with UTUC undergoing RNU with and without LND using templates similar to those described in the study above reported that patients with muscle-invasive (pT2) renal pelvic tumors who received template-based LND had a higher CSS compared to those treated with RNU alone. 20 The main strengths of the current study are the large sample size and the fact that all patients were treated in the contemporary era. Nevertheless, its observational nature means that the results are susceptible to bias due to unmeasured or residual confounding. It is possible that the extent of LND may be modified by the surgeon based on his or her perception of cancer severity or therapeutic intent. For example, if a surgeon who believes that LND has no therapeutic value encounters palpably abnormal LNs during RNU, he or she may simply sample a few of these LNs to confirm the presence of LN metastases and go no further. Although LN metastases were detected less frequently in patients with lower LN yields, we cannot rule out that the true incidence of LN metastases or total metastatic LN burden was higher among patients who underwent limited versus more extensive LND. Although it also is possible that the opposite is true, namely that patients who are expected to have pN1 disease are subjected to more extensive LND, such an association would tend to bias the results toward the null. Other factors also might influence the extent of surgical dissection such as patient comorbidity, body habitus, and prior surgery, all of which are factors that also could influence the risk of complications and all-cause mortality. A lack of data pertaining to cause of death precluded an analysis of the relationship between LN yield and cancer-specific mortality. Although we controlled for patient age and comorbidity status in the multivariable analyses, the Charlson Comorbidity Index may not capture all nuances of an individual patient's comorbidities, such that the potential for residual confounding remains. Information pertaining to prior endoscopic treatment of the primary tumor, which has been associated with worse outcomes among patients with high grade disease, 21 was not available. Finally, it must be acknowledged that LN yield is an imperfect surrogate of extent of LND because it may be related to other factors such as the manner in which LNs are submitted (en bloc or as separate packets) and the thoroughness of subsequent histopathologic examination.
The results of the current study indicate that LND is used infrequently in patients with UTUC and provides evidence of an association between increasing LN yield and longer survival in this population. It must be acknowledged that the question of therapeutic benefit from extended LND is complex, and answering it will require a firm understanding of LN drainage patterns and prospective study in appropriately selected patients. Although the low incidence of UTUC and the inherent difficulties in randomizing surgical interventions for patients with a highly lethal disease make a randomized trial challenging to perform, the findings of the current study suggest that this question is important to address given the high degree of variability in existing practice and the potential for significant patient benefit.
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